ZACKS
Search documents
PTC Therapeutics (PTCT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
ZACKS· 2026-02-20 01:31
Core Insights - PTC Therapeutics reported a revenue of $164.68 million for Q4 2025, marking a year-over-year decline of 22.8% and significantly missing the Zacks Consensus Estimate of $304.72 million by 45.96% [1] - The company experienced an EPS of -$1.67, which is a substantial drop from -$0.24 a year ago, resulting in an EPS surprise of -700.58% compared to the consensus estimate of -$0.21 [1] Revenue Breakdown - Net product revenue reached $183.99 million, exceeding the four-analyst average estimate of $174.53 million, reflecting an 18.9% year-over-year increase [4] - Royalty revenue was reported at $79.39 million, surpassing the average estimate of $70.77 million, with a year-over-year change of 36.5% [4] - Net product revenue from Translarna was $39 million, slightly below the average estimate of $40.42 million, showing a significant decline of 58.4% year-over-year [4] - Net product revenue from Emflaza was $27.1 million, which is lower than the estimated $29.58 million, representing a 46.3% decrease compared to the previous year [4] - Collaboration and license revenue was reported at -$0.07 million, a stark contrast to the average estimate of $118.82 million [4] Stock Performance - PTC Therapeutics shares have returned -8.8% over the past month, compared to a -0.8% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]
Compared to Estimates, RingCentral (RNG) Q4 Earnings: A Look at Key Metrics
ZACKS· 2026-02-20 01:31
Core Insights - RingCentral reported revenue of $644.03 million for Q4 2025, a year-over-year increase of 4.8% and an EPS of $1.18 compared to $0.98 a year ago, exceeding the Zacks Consensus Estimate of $642.29 million by 0.27% [1] - The company delivered an EPS surprise of 3.69%, with the consensus EPS estimate being $1.14 [1] Financial Performance Metrics - Gross Margin - Non-GAAP Other was reported at -10.6%, below the four-analyst average estimate of -9.5% [4] - Gross Margin - Non-GAAP Subscriptions was 80.4%, slightly below the four-analyst average estimate of 80.6% [4] - Subscription revenues reached $622.22 million, surpassing the four-analyst average estimate of $621.84 million, reflecting a year-over-year change of 5.5% [4] - Revenues from Other segments were $21.82 million, exceeding the average estimate of $20.44 million, but showing a year-over-year decline of 12.2% [4] Stock Performance - Shares of RingCentral have returned 14.1% over the past month, contrasting with the Zacks S&P 500 composite's decline of 0.8% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]
World Kinect (WKC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
ZACKS· 2026-02-20 01:31
Core Insights - World Kinect (WKC) reported a revenue of $9.03 billion for the quarter ended December 2025, reflecting a year-over-year decline of 7.5% and an EPS of $0.30 compared to $0.62 a year ago [1] - The reported revenue fell short of the Zacks Consensus Estimate of $9.22 billion, resulting in a surprise of -2.12%, while the EPS surprise was -36.17% against a consensus estimate of $0.47 [1] Financial Performance Metrics - The company’s performance metrics indicate a decline in operational income across various segments: - Land: Income loss of $292.2 million compared to an average estimate of $12.35 million [4] - Aviation: Income of $54.2 million versus an average estimate of $69.35 million [4] - Marine: Income of $7 million compared to an average estimate of $9.47 million [4] - Volume metrics also showed discrepancies with: - Land volume at 1,392.70 million gallons against an average estimate of 1,412.81 million gallons [4] - Aviation volume at 1,763.10 million gallons compared to an average estimate of 1,771.94 million gallons [4] Stock Performance - Over the past month, shares of World Kinect have returned -0.8%, aligning with the Zacks S&P 500 composite's -0.8% change, and the stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]
Savers Value (SVV) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
ZACKS· 2026-02-20 01:31
Core Insights - Savers Value Village (SVV) reported revenue of $464.67 million for the quarter ended December 2025, marking a year-over-year increase of 15.6% [1] - The earnings per share (EPS) for the same period was $0.15, compared to $0.10 a year ago, reflecting a positive growth trend [1] - The reported revenue was slightly below the Zacks Consensus Estimate of $464.69 million, resulting in a revenue surprise of -0.01% [1] - The EPS fell short of the consensus estimate of $0.16, leading to an EPS surprise of -3.23% [1] Financial Performance Metrics - Comparable Store Sales Growth was reported at 5.4%, exceeding the average estimate of 4.3% from three analysts [4] - The total number of stores was 367, which is below the average estimate of 376 from two analysts [4] - In the United States, the number of stores was 179, compared to the average estimate of 186 [4] - In Canada, the number of stores was 170, slightly below the average estimate of 172 [4] - Comparable Store Sales Growth in the United States was 8.8%, surpassing the average estimate of 6.4% [4] - Comparable Store Sales Growth in Canada was 0.7%, exceeding the average estimate of 0.3% [4] - U.S. Retail revenue was $265.88 million, above the average estimate of $258.08 million, representing a year-over-year increase of 20.6% [4] - Other revenue was reported at $33.9 million, slightly below the average estimate of $34.18 million, with a year-over-year change of 11.5% [4] - Canada Retail revenue was $164.89 million, exceeding the average estimate of $161.06 million, reflecting a year-over-year increase of 9.1% [4] Stock Performance - Shares of Savers Value have returned +1.1% over the past month, while the Zacks S&P 500 composite has decreased by -0.8% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]
Non-Tech Stocks Also Deliver Big Gains
ZACKS· 2026-02-20 01:20
If there’s one thing that’s undoubtedly true over the past decade, it’s that technology stocks have been blistering hot.And it’s been for very understandable reasons – many of these companies’ products have entirely changed the way the world behaves. People stay solely connected through digital channels such as social media, students are now taking their exams online, and consumers are even utilizing digital apps that allow for grocery delivery.But while all that sounds fun and exciting, many have overlooke ...
Alliant Energy (LNT) Beats Q4 Earnings and Revenue Estimates
ZACKS· 2026-02-20 01:10
Core Insights - Alliant Energy reported quarterly earnings of $0.6 per share, exceeding the Zacks Consensus Estimate of $0.58 per share, but down from $0.7 per share a year ago, resulting in an earnings surprise of +3.45% [1] - The company achieved revenues of $1.06 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 13.45% and up from $976 million year-over-year [2] - Alliant Energy shares have increased approximately 7% year-to-date, outperforming the S&P 500's gain of 0.5% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.85 on revenues of $1.15 billion, and for the current fiscal year, it is $3.43 on revenues of $4.37 billion [7] - The estimate revisions trend for Alliant Energy was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Utility - Electric Power industry is currently ranked in the top 36% of over 250 Zacks industries, suggesting that companies in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8] - Another company in the same industry, Algonquin Power & Utilities, is expected to report a quarterly earnings decline of -33.3% with revenues projected at $568.72 million, down 2.8% from the previous year [9][10]
Compared to Estimates, Universal Display (OLED) Q4 Earnings: A Look at Key Metrics
ZACKS· 2026-02-20 01:01
Universal Display Corp. (OLED) reported $172.93 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 6.6%. EPS of $1.39 for the same period compares to $1.22 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $173.25 million, representing a surprise of -0.19%. The company delivered an EPS surprise of +9.02%, with the consensus EPS estimate being $1.28.While investors closely watch year-over-year changes in headline numbers -- revenue and ...
Compared to Estimates, WillScot (WSC) Q4 Earnings: A Look at Key Metrics
ZACKS· 2026-02-20 01:01
WillScot (WSC) reported $565.97 million in revenue for the quarter ended December 2025, representing a year-over-year decline of 6.1%. EPS of $0.29 for the same period compares to $0.49 a year ago.The reported revenue represents a surprise of +3.94% over the Zacks Consensus Estimate of $544.51 million. With the consensus EPS estimate being $0.33, the EPS surprise was -12.91%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine ...
AMN Healthcare (AMN) Reports Q4 Earnings: What Key Metrics Have to Say
ZACKS· 2026-02-20 01:01
For the quarter ended December 2025, AMN Healthcare Services (AMN) reported revenue of $748.23 million, up 1.8% over the same period last year. EPS came in at $0.22, compared to $0.75 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $723.87 million, representing a surprise of +3.37%. The company delivered an EPS surprise of -1.12%, with the consensus EPS estimate being $0.22.While investors closely watch year-over-year changes in headline numbers -- revenue and earnin ...
PTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue Estimates
ZACKS· 2026-02-20 01:01
PTC Therapeutics (PTCT) came out with a quarterly loss of $1.67 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.24 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -700.58%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $1.19 per share when it actually produced earnings of $0.2, delivering a surprise of +116.81%.Over the last four quarters ...